文献速递神经核医学

2018年NIA-AA研究框架下的脑PET淀粉样蛋白与神经退行性生物标志物:探讨临床-生物标志物不匹配及社会人口学参数的个体化方法

Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-02-13

研究纳入108例老年人(对照组27例、遗忘型轻度认知障碍43例、轻度很可能阿尔茨海默病38例),基于2018年NIA-AA研究框架的PET分期系统比较淀粉样蛋白阳性(A+)和代谢减低((N)+)比例,并对临床-生物标志物不匹配病例重新评估[18F]FDG-PET模式。结果显示阿尔茨海默病组A+和(N)+比例更高,aMCI组(N)分期与对照组不同,[18F]FDG-PET可提供额外假设,低教育和社会经济地位与无生物标志物改变的痴呆相关。

要点

  • 基于PET的NIA-AA分期显示阿尔茨海默病组A+和(N)+比例高于其他组。
  • aMCI组(N)+比例高于对照组但A分期差异无统计学显著性。
  • 淀粉样蛋白阳性与AD典型代谢减低模式相关。

核心结论

  • 基于PET的分期系统揭示了阿尔茨海默病组与其他组之间显著的A(N)差异,而aMCI与对照组具有不同的(N)分期,解释了aMCI的认知障碍。
  • [18F]FDG-PET可超越单纯的(N)分期使用,因为它为临床-生物标志物不匹配病例提供了替代假设。
  • AD代谢减低模式与淀粉样蛋白阳性相关。
  • 低教育和社会经济地位与无生物标志物改变的痴呆相关。

研究设计与样本

  • 纳入108例老年人,临床分类为对照组27例、遗忘型轻度认知障碍43例、轻度很可能阿尔茨海默病38例。
  • 评估A(N)特征,并将[18F]FDG-PET神经退行性模式分类为AD典型或非典型。
  • 当临床分类与PET分期不一致(临床-生物标志物不匹配)时对图像进行重新评估。
  • 探讨不匹配与社会人口学及教育特征之间的关联。

主要发现

  • 阿尔茨海默病组呈现更高的A+和(N)+比例。
  • aMCI组A+和(N)+个体比例高于对照组,但A分期无统计学显著性。
  • 淀粉样蛋白阳性与AD典型(N)+代谢减低模式之间存在显著关联。
  • 轻度很可能AD组和对照组中所有A-(N)+病例均见非AD(N)+代谢减低,[18F]FDG-PET模式将其分类为SNAP及1例很可能额颞叶变性。
  • 很可能AD组中所有A-(N)-病例均受教育年限少于4年且社会经济地位较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [18F]FDG-PET and [11C]PIB-PET are validated as neurodegeneration and amyloid biomarkers of Alzheimer's disease (AD). We used a PET staging system based on the 2018 NIA-AA research framework to compare the proportion of amyloid positivity (A+) and hypometabolism ((N)+) in cases of mild probable AD, amnestic mild cognitive impairment (aMCI), and healthy controls, incorporating an additional classification of abnormal [18F]FDG-PET patterns and investigating the co-occurrence of such with A+, exploring [18F]FDG-PET to generate hypotheses in cases presenting with clinical-biomarker "mismatches." METHODS: Elderly individuals (N = 108) clinically classified as controls (N = 27), aMCI (N = 43) or mild probable AD (N = 38) were included. Authors assessed their A(N) profiles and classified [18F]FDG-PET neurodegenerative patterns as typical or non-typical of AD, performing re-assessments of images whenever clinical classification was in disagreement with the PET staging (clinical-biomarker "mismatches"). We also investigated associations between "mismatches" and sociodemographic and educational characteristics. RESULTS: AD presented with higher rates of A+ and (N)+. There was also a higher proportion of A+ and (N)+ individuals in the aMCI group in comparison to controls, however without statistical significance regarding the A staging. There was a significant association between amyloid positivity and AD (N)+ hypometabolic patterns typical of AD. Non-AD (N)+ hypometabolism was seen in all A- (N)+ cases in the mild probable AD and control groups and [18F]FDG-PET patterns classified such individuals as "SNAP" and one as probable frontotemporal lobar degeneration. All A- (N)- cases in the probable AD group had less than 4 years of formal education and lower socioeconomic status (SES). CONCLUSION: The PET-based staging system unveiled significant A(N) differences between AD and the other groups, whereas aMCI and controls had different (N) staging, explaining the cognitive impairment in aMCI. [18F]FDG-PET could be used beyond simple (N) staging, since it provided alternative hypotheses to cases with clinical-biomarker "mismatches." An AD hypometabolic pattern correlated with amyloid positivity. Low education and SES were related to dementia in the absence of biomarker changes.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Coutinho AM, Busatto GF, de Gobbi Porto FH, et al. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. Eur J Nucl Med Mol Imaging. 2020. PMID: 32055966. doi:10.1007/s00259-020-04714-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。